These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34935177)

  • 1. Robust group sequential designs for trials with survival endpoints and delayed response.
    Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
    Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.
    Prior TJ
    Stat Methods Med Res; 2020 Dec; 29(12):3525-3532. PubMed ID: 32522077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies.
    Hasegawa T
    Pharm Stat; 2016 Sep; 15(5):412-9. PubMed ID: 27353855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
    Jiménez JL; Stalbovskaya V; Jones B
    Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies.
    Hasegawa T
    Pharm Stat; 2014; 13(2):128-35. PubMed ID: 24497461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
    Wu J; Li Y; Zhu L
    J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simulation-free group sequential design with max-combo tests in the presence of non-proportional hazards.
    Wang L; Luo X; Zheng C
    Pharm Stat; 2021 Jul; 20(4):879-897. PubMed ID: 33759337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Yang M; Hua Z; Xue L; Hu M
    J Biopharm Stat; 2020 Mar; 30(2):244-266. PubMed ID: 31288599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance.
    Magirr D; Jiménez JL
    Clin Trials; 2022 Apr; 19(2):201-210. PubMed ID: 35257619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
    Yang S
    Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On information fraction for Fleming-Harrington type weighted log-rank tests in a group-sequential clinical trial design.
    Kundu MG; Sarkar J
    Stat Med; 2021 May; 40(10):2321-2338. PubMed ID: 33624861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials.
    Kaneko Y; Morita S
    J Biopharm Stat; 2024 Aug; 34(5):626-645. PubMed ID: 37585719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing therapeutic cancer vaccine trials with delayed treatment effect.
    Xu Z; Zhen B; Park Y; Zhu B
    Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential tests for non-proportional hazards data.
    Brückner M; Brannath W
    Lifetime Data Anal; 2017 Jul; 23(3):339-352. PubMed ID: 26969674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-proportional hazards in immuno-oncology: Is an old perspective needed?
    Magirr D
    Pharm Stat; 2021 May; 20(3):512-527. PubMed ID: 33350587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical and practical considerations in designing of immuno-oncology trials.
    Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
    J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratified modestly weighted log-rank tests in settings with an anticipated delayed separation of survival curves.
    Magirr D; Jiménez JL
    Biom J; 2023 Apr; 65(4):e2200126. PubMed ID: 36732918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.